Outset Medical general counsel sells shares worth $2,027

Published 08/01/2025, 01:30
Outset Medical general counsel sells shares worth $2,027

John L. Brottem, the General Counsel of Outset Medical (TASE:PMCN), Inc. (NASDAQ:OM), recently sold 1,572 shares of the company's common stock. The shares were sold at a price of $1.29 each, totaling $2,027. Following the transaction, Brottem holds 225,520 shares in the company. The transaction comes amid challenging market conditions for Outset Medical, which has seen its stock decline nearly 80% over the past year. According to InvestingPro analysis, the company's current market capitalization stands at $57.27 million, with the stock showing significant volatility.

This sale was not a discretionary trade but was made to cover tax withholding obligations related to previously earned performance stock units. These units were vested and released on January 6, 2025, and the sale was executed as a "sell to cover" transaction. InvestingPro analysis indicates the company is currently undervalued, with additional insights available through their comprehensive Pro Research Report, which covers over 1,400 US stocks including Outset Medical.

In other recent news, Outset Medical, Inc. has reported a strong financial performance for the third quarter of 2024. The company highlighted a record recurring revenue, significant increase in treatment and service revenue, and an upward revision of their revenue guidance for the year. Q3 revenue reached $28.7 million, surpassing predictions, with treatment revenue up by 14% and service revenue by 22%. Furthermore, gross margin improved to 36.4%, with a net loss declining by 43% from the previous year. The company raised its 2024 revenue guidance to approximately $112 million, with a gross margin expected in the mid-30% range. Despite a net loss of $20.2 million for the quarter, recurring revenue now constitutes about 60% of total revenue, indicating a positive financial trajectory. Finally, Outset Medical expressed optimism about long-term growth, with a strong order pipeline and a solid recurring revenue foundation for 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.